Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

By D. Singer, G. Albers, J. Dalen, M. Fang, Alan S. Go, J. Halperin, Gregory Y. H. Lip, Warren J. Manning. Chest, 2008

801 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

GRADE guidelines: 9. Rating up the quality of evidence. (2011, background): “Supplementary indirect evidence from randomized trials that have demonstrated large reductions in the RR of thrombosis with anticoagulation in analogous conditions such as atrial fibrillation further increases our confidence in the beneficial effect of anticoagulation [9].”
Guidelines on oral anticoagulation with warfarin – fourth edition (2011, background): “Evidence comparing the efficacy of different anticoagulation regimens and considering bleeding risk suggests an optimum INR target of 2Æ5 (Singer et al, 2008), which is more effective than lowintensity fixed dose warfarin plus aspirin (Stroke Prevention in Atrial Fibrillation III trial) (Stroke…”
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, neutral): “Recommendations for antithrombotic therapy should be based on the presence (or absence) of risk factors for stroke and thromboembolism, and we refer further to the recent guidelines of the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology.(516,517)”